Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60).

Abstract:

:The resistance to all trans retinoic acid (ATRA) differentiating treatment is a consequence, in most of the cases, of either increased catabolism or down regulation of ATRA uptake. Recently, we have shown that ATRA efficiency to differentiate HL-60 cells was enhanced about 30 times after its incorporation into Low Density Lipoprotein (ATRA-LDL). Here, we attempted to differentiate the ATRA-resistant HL-60 cells by ATRA-LDL at high concentrations up to 10 microM. No significant differentiating effect was observed, although the LDL receptor sites were evidenced in these cells. To increase the number of LDL receptors, the cells were pre-incubated in lipoprotein-deprived serum medium and compactin (2 microM), both ATRA and ATRA-LDL induced gradual increase of cell differentiation (35%+/-1 and 51.5%+/-5 at 10 microM of ATRA and ATRA-LDL respectively). At 2 and 8 microM, the intracellular concentrations of ATRA were respectively three and four times higher when incorporated into LDL. In addition, ATRA-LDL, in the medium, was better protected against degradation than ATRA. The surprising restoration of free ATRA sensitivity after treatment with compactin suggested the implication of new mechanisms unrelated to the LDL-receptor endocytosis but involving the non-sterol pathway.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Gueddari N,Madoulet C,Lefebvre P,Berthou L,Chomienne C,Jardillier JC

doi

10.1016/s0145-2126(00)00019-9

keywords:

subject

Has Abstract

pub_date

2000-06-01 00:00:00

pages

543-8

issue

6

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(00)00019-9

journal_volume

24

pub_type

杂志文章
  • Phenotypic and functional characterization of mobilized peripheral blood CD34+ cells coexpressing different levels of c-Kit.

    abstract::In this report we evaluated the exact expression pattern of c-Kit on mobilized peripheral blood (PB) CD34+ cells. Using a monoclonal antibody against CD117 antigen (95C3), flow cytometric analysis revealed that approximately 25% of the mobilized PB CD34+ cells coexpress c-Kit. This cell fraction showed a considerable ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(98)00002-2

    authors: Kuçi S,Taylor G,Neu S,Schumm M,Niethammer D,Handgretinger R

    更新日期:1998-04-01 00:00:00

  • Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia.

    abstract::Overexpression of the Wilms' tumor gene 1 (WT1) was observed in most leukemia cells. In addition to four major isoforms of WT1, an N-terminally truncated isoforms (sWT1) has been identified. We separately quantified the transcript levels of sWT1 and full-length WT1 (fWT1) in 237 patients with acute myeloid leukemia (A...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2011.01.002

    authors: Ishikawa Y,Kiyoi H,Naoe T

    更新日期:2011-05-01 00:00:00

  • Low-dose radiotherapy (2×2 g) versus low doses and rituximab in the treatment of marginal zone b-cell lymphoma previously untreated.

    abstract::Radiotherapy (RT)is considered the treatment of choice in patients with Extra-nodal marginal zone lymphoma (EMZL) at early stage, but the presence of late toxicities has been limited the acceptance. Recently, low doses of RT LDR) (2 x 2 Gy) and the use of limited fields has been observed that retain the efficacy but e...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2020.106443

    authors: Aviles A,Cleto S

    更新日期:2020-11-01 00:00:00

  • Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL).

    abstract::MicroRNAs (miRNAs) are small endogenous RNA molecules that regulate gene expression at the post-transcriptional level through its sequence complementation with target mRNAs. An individual miRNA species can simultaneously influence the expression of multiple genes and conversely, several miRNAs can synchronously contro...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2013.08.020

    authors: Mazan-Mamczarz K,Gartenhaus RB

    更新日期:2013-11-01 00:00:00

  • Balance of NF-kappaB and p38 MAPK is a determinant of radiosensitivity of the AML-2 and its doxorubicin-resistant cell lines.

    abstract::This study investigated radioresistance mechanisms in the doxorubicin-resistant acute myelogenous leukemia (AML)-2/DX100. AML-2/DX100 also showed resistance to radiation. AML-2/DX100 characterized by down-regulated catalase expression was supersensitive to exogenous hydrogen peroxide whereas they increased defense mec...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.11.006

    authors: Choi CH,Xu H,Bark H,Lee TB,Yun J,Kang SI,Oh YK

    更新日期:2007-09-01 00:00:00

  • Effect of prostaglandin E2 on gamma-interferon and 1,25(OH)2D3 vitamin D3-induced c-myc reduction during HL-60 cell differentiation.

    abstract::The effect of prostaglandin E2 (PGE2) on the reduction of c-myc expression during the differentiation of the human leukemic cell line, HL-60, was examined. PGE2, a potent inducer of intracellular cyclic AMP (cAMP) in HL-60 cells, augmented monocyte-associated cell surface antigens induced by human gamma-interferon (IF...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(88)90090-2

    authors: Matsui T,Nakao Y,Koizumi T,Katakami Y,Takahashi R,Mihara K,Sugiyama T,Fujita T

    更新日期:1988-01-01 00:00:00

  • A novel Ph1 chromosome positive cell line established from a patient with chronic myelogenous leukemia in blastic crisis.

    abstract::A novel Philadelphia (Ph1) chromosome positive cell line, designated KYO-1, was established from the peripheral blood of a patient with chronic myelogenous leukemia (CML) in blastic crisis. Although this line had a unique capacity to differentiate spontaneously along the erythroid and monocytoid lineages as evidenced ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(85)90314-5

    authors: Ohkubo T,Kamamoto T,Kita K,Hiraoka A,Yoshida Y,Uchino H

    更新日期:1985-01-01 00:00:00

  • Aven overexpression: association with poor prognosis in childhood acute lymphoblastic leukemia.

    abstract::Aven expression has recently been identified as an anti-apoptotic protein. In this study, Aven expression in 91 children with acute lymphoblastic leukemia (ALL) was investigated for possible correlation with clinical features at diagnosis and treatment outcome. Aven expression was found to be higher in patients >or=10...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.11.001

    authors: Choi J,Hwang YK,Sung KW,Kim DH,Yoo KH,Jung HL,Koo HH

    更新日期:2006-08-01 00:00:00

  • Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia.

    abstract::We have demonstrated that constitutive signal transducer and activator of transcription (STAT) 3 activity, observed in approximately 50% of acute myeloid leukemia (AML) cases, is associated with adverse treatment outcome. Constitutive STAT3 activation may result from the expression of oncogenic protein tyrosine kinase...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2007.11.035

    authors: Ghoshal Gupta S,Baumann H,Wetzler M

    更新日期:2008-07-01 00:00:00

  • Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-gamma.

    abstract::When cells were incubated in the presence of both interferon-gamma (IFN-gamma) and all-trans retinoic acid (ATRA), the concentration of IFN-gamma required to induce apoptosis of B-cell lymphoma cells was much lower than that required for myeloid or erythroid cell lines. The concentration of IFN-gamma that effectively ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(01)00202-8

    authors: Niitsu N,Higashihara M,Honma Y

    更新日期:2002-08-01 00:00:00

  • Minimal residual disease in vitro of a pre-B-lymphoma.

    abstract::We have studied the survival of clonogenic neoplastic cells of a murine pre-B-lymphoma (BCl-1) of the spleen in culture. We have found quantitative deficiencies such as reduced surface adherence of stromal cells and impaired CFU-F (colony forming units-fibroblast) and pre-CFU-F colony and layer formation in stromal cu...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(93)90088-3

    authors: Prindull G,Ben-Ishay Z,Bergholz M,Prindull B

    更新日期:1993-07-01 00:00:00

  • Responsiveness to stem cell factor (SCF) of peripheral blood colony-forming cells from patients with myelodysplastic syndromes (MDS).

    abstract::We have previously reported that serum stem factor (SCF) levels are significantly lower in patients with myelodysplastic syndrome (MDS) than normal controls. We have now studied the effects of adding SCF to cultures of blood mononuclear cells from patients with MDS and normal subjects. Three of 17 patients with MDS sh...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(95)00034-l

    authors: Masters GS,Baines P,Tang C,Bowen D,Burnett AK

    更新日期:1995-08-01 00:00:00

  • The correlation of adenosine deaminase and purine nucleoside phosphorylase activities in human lymphocytes subpopulations and in various lymphoid malignancies.

    abstract::Adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) were measured in normal human and in malignant lymphoid cells. Thymocytes had high ADA activity (21.2 +/- 6.8 10(3) nM/h/mg) and low PNP activity (1.2 +/- 0.6), whereas T peripheral blood lymphocytes (PBL) had low ADA activity (1.20 +/- 0.22) and high...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(82)90027-3

    authors: Demeocq F,Viallard JL,Boumsell L,Richard Y,Chassagne J,Plagne R,Lemerle J,Bernard A

    更新日期:1982-01-01 00:00:00

  • The discovery of endothelial progenitor cells. An historical review.

    abstract::Although the earliest sites of hematopoietic cell and endothelial cell differentiation in the yolk sac blood islands were identified about 100 years ago, cells with hemangioblast properties have not yet been identified in vivo. Endothelial cells differentiate from angioblasts in the embryo and from endothelial progeni...

    journal_title:Leukemia research

    pub_type: 历史文章,杂志文章,评审

    doi:10.1016/j.leukres.2006.10.014

    authors: Ribatti D

    更新日期:2007-04-01 00:00:00

  • Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts.

    abstract::Despite the high effectiveness of various P-glycoprotein (P-gp) modulating substances in vitro their clinical value e.g. for combination treatment of acute myelogenous leukemias (AML) remains still unclear. This might be explainable by recent findings that other factors than P-gp (e.g. the multidrug resistance associa...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(98)00192-1

    authors: Brügger D,Herbart H,Gekeler V,Seitz G,Liu C,Klingebiel T,Orlikowsky T,Einsele H,Denzlinger C,Bader P,Niethammer D,Beck JF

    更新日期:1999-05-01 00:00:00

  • A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.

    abstract::Despite initial remissions, most patients with Ph chromosome positive (Ph(+)) acute leukemia (AL) become refractory to tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib. This study was designed to determine if targeting the interleukin-3 receptor (IL-3R) with a diphtheria toxin fusion protein (DT(388)IL...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.12.008

    authors: Kim HP,Frankel AE,Hogge DE

    更新日期:2010-08-01 00:00:00

  • Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells.

    abstract::Imatinib mesylate, a Bcr/Abl tyrosine kinase inhibitor, is widely used in treating chronic myeloid leukemia. However, drug-resistance of leukemia cells becomes an emergent problem. Herein, various flavonoids were screened for applicability in leukemia treatment, and 3-hydroxyflavone (3-HF) was found to be most effecti...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.05.018

    authors: Kim JH,Song M,Kang GH,Lee ER,Choi HY,Lee C,Kim JH,Kim Y,Koo BN,Cho SG

    更新日期:2012-09-01 00:00:00

  • Dietary bioflavonoids induce apoptosis in human leukemia cells.

    abstract::Dietary bioflavonoids are secondary metabolites of plants that are known to have a variety of bio-effects, including anti-cancer activity. In this study, we examined the effects of flavonoids on the growth of human leukemia cells and found that certain flavonoids induce apoptosis in a variety of human leukemia cells. ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.11.015

    authors: Matsui J,Kiyokawa N,Takenouchi H,Taguchi T,Suzuki K,Shiozawa Y,Saito M,Tang WR,Katagiri YU,Okita H,Fujimoto J

    更新日期:2005-05-01 00:00:00

  • Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.

    abstract::Inhibition of cyclooxygenase 2 (COX-2) by the selective COX-2 inhibitor celecoxib has been suggested as potentially useful for B-cell lymphoma therapy. However, additional pharmacological activities of celecoxib have been discovered and have challenged the notion that its antitumor effects are mediated primarily via t...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.09.028

    authors: Chen ST,Thomas S,Gaffney KJ,Louie SG,Petasis NA,Schönthal AH

    更新日期:2010-02-01 00:00:00

  • Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia.

    abstract::We describe a 79-year-old man who had massive pleural effusion and a proliferation of prolymphocytic leukemia cells in the peripheral blood, bone marrow, and pleural effusion fluid. Immunophenotyping of leukemia cells revealed either CD3+CD4+CD8-CD25+ or CD3+CD4+CD8+CD25+. The antibody against human T-cell lymphotropi...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.02.029

    authors: Ogasawara T,Narita C,Kawauchi K

    更新日期:2007-03-01 00:00:00

  • Characteristics of the inhibition of human promyelocytic leukaemia HL60 cell growth by S-D-lactoylglutathione in vitro.

    abstract::The mechanism of the inhibition of proliferation of human leukaemia 60 (HL60) cells by S-D-lactoylglutathione in vitro was investigated. The median inhibitory concentration IC50 value was 66 microM (95% C.I. 50-87 microM; n = 18). The inhibition of leukaemia cell growth required exposure of HL60 cells to S-D-lactoylgl...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(93)90017-f

    authors: Edwards L,Clelland JD,Thornalley PJ

    更新日期:1993-04-01 00:00:00

  • The reproducibility of acute lymphoblastic leukemia phenotype determinations: evaluation of monoclonal antibody and conventional hematopoietic markers.

    abstract::Peripheral blood and/or bone marrow lymphoblasts from 25 patients with acute lymphoblastic leukemia (ALL) were tested with a panel of monoclonal antibodies (MoAbs) and conventional hematopoietic markers by three different laboratories. The results were analysed to evaluate the reproducibility of ALL phenotype determin...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(86)90083-4

    authors: Sobol RE,Mick R,LeBien TW,Ozer H,Minowada J,Anderson K,Ellison RR,Cuttner J,Morrison A,Richards F 2nd

    更新日期:1986-01-01 00:00:00

  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

    abstract::There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation an...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2020.106385

    authors: Goldberg AD,Atallah E,Rizzieri D,Walter RB,Chung KY,Spira A,Stock W,Tallman MS,Cruz HG,Boni J,Havenith KEG,Chao G,Feingold JM,Wuerthner J,Solh M

    更新日期:2020-08-01 00:00:00

  • Preclinical studies of a panel of 12 monoclonal antibodies in view of bone marrow purging in acute lymphoblastic leukemia.

    abstract::We analysed the optimal conditions for autologous bone marrow purging using complement binding monoclonal antibodies (mAbs). Twelve mAbs belonging to four clusters (CD9, CD10, CD19, CD24), alone or combined were evaluated by using direct cytotoxicity and clonogenic assays. We observed the following data: (1) optimal c...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(87)90117-2

    authors: Racadot E,Herve P,Lamy B,Peters A

    更新日期:1987-01-01 00:00:00

  • Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.

    abstract::We examined the effect of deferasirox (DFX) on CD34+ hematopoietic progenitors from MDS patients. Progressive, dose-dependent suppression of MDS progenitor proliferation in culture was observed with DFX concentrations ranging from 5 μM to 20 μM. This effect was more pronounced in MDS compared to CD34+ progenitors isol...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.03.018

    authors: Pullarkat V,Sehgal A,Li L,Meng Z,Lin A,Forman S,Bhatia R

    更新日期:2012-08-01 00:00:00

  • Cytogenetic studies on rat thymic lymphomas induced by N-propyl-N-nitrosourea.

    abstract::N-Propyl-N-nitrosourea (PNU) was proved to be a strong leukemogen, which induces myelogenous leukemia or thymic lymphoma in rats. BUF/Mna rats and F344 rats were the strain most susceptible to thymic lymphomagenic activity of PNU. In addition, F1 rats between BUF/Mna and WKY rats were also susceptible to PNU-lymphomag...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(88)90091-4

    authors: Ogiu T,Utsumi KR,Fukami H,Matsuyama M

    更新日期:1988-01-01 00:00:00

  • Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.

    abstract::DNA aneuploidy has been used as a genetic marker of malignancy in multiple myeloma (MM). CD38 and CD138 expression and absence of CD22 and CD19 may define plasmacells (PC). Several authors support evidences of circulating plasmacells, and their role in relapse after autologous stem cell transplantation has been hypoth...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2003.09.015

    authors: Santonocito AM,Consoli U,Bagnato S,Milone G,Palumbo GA,Di Raimondo F,Stagno F,Guglielmo P,Giustolisi R

    更新日期:2004-05-01 00:00:00

  • Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literature.

    abstract::The aim of this study is to detect the biologic and/or prognostic significance of survivin (S) and effector protease receptor 1: EPR-1 (E) expression in acute leukemias (34 ALL and 40 AML) by using RT-PCR. S and E expressions were found in 83.8 and 20.3% of the cases, respectively. S was detected in 90%, 76.5% and E w...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.01.005

    authors: Oto OA,Paydas S,Tanriverdi K,Seydaoglu G,Yavuz S,Disel U

    更新日期:2007-11-01 00:00:00

  • Continuous intravenous infusion of high dose recombinant interleukin 2 for advanced lymphomas--a phase II study.

    abstract::The prognosis of patients with advanced refractory lymphoma remains poor. We have carried out a Phase II study of continuous high dose intravenous recombinant interleukin 2 alone without LAK cells in this group of patients. Eight patients have so far been treated, 4 with non-Hodgkins lymphoma and 4 with Hodgkins disea...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/0145-2126(91)90053-v

    authors: Lim SH,Worman CP,Callaghan T,Jewell A,Smith MP,Goldstone AH

    更新日期:1991-01-01 00:00:00

  • Karyotype at diagnosis, subsequent leukemic transformation and survival in myelodysplastic syndrome. Czechoslovak MDS Cooperative Group.

    abstract::240 patients with MDS studied cytogenetically at diagnosis between 1981 and 1990 were followed until death or until April 1992 to evaluate the prognostic significance of FAB classification, age and karyotype. 61 patients (25.4%) subsequently transformed into AML and 176 (73.3%) died during the follow-up period. Patien...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(94)00131-s

    authors: Musilová J,Michalová K,Zemanová Z,Neuwirthová R,Dohnalová A

    更新日期:1995-05-01 00:00:00